Aribio to Participate in BIO-Europe 2025, Accelerating Global Partnering
Aribio announced on October 27 that it will participate in BIO-Europe 2025, the world’s largest bio partnering conference, to be held in Vienna, Austria, from November 3 to 5.
BIO-Europe is a leading global networking event where pharmaceutical companies, bio-innovation firms, and investors from around the world gather to actively engage in technology transfer for new drugs and attract investments. Aribio will be represented by Fred Kim, Head of the U.S. office, and Dr. Tanya Xi (MD, PhD, MBA), Head of Business Development. The company has confirmed more than 50 partnering meetings with global pharmaceutical companies and institutional investors.
The company plans to focus discussions on the following: additional exclusive licensing negotiations for the Alzheimer’s disease treatment “AR1001,” which is currently in global Phase 3 clinical trials; development collaboration for the cognitive function improvement brain stimulation medical device “Herzion”; and joint development and investment attraction for new pipelines.
Fred Kim stated, “There is significant interest from global pharmaceutical companies in Aribio’s Alzheimer’s treatment and related pipelines. Intensive discussions are expected to take place regarding the exclusive sales rights for AR1001 in North America and Europe, as it enters the final stage of Phase 3 clinical trials.”
Dr. Tanya Xi commented, “This event is an important opportunity to establish concrete global partnerships. We will actively seek collaborations in various areas, including next-generation new drug pipelines and medical device development programs.”
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "I Will Give Them a Chance for Self-Examination": Chinese Scientific Community Shaken by Influencer's Preemptive Whistleblowing
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Aribio is leading the development of treatments for neurodegenerative diseases and is expanding its strategic collaborations through major global partnering events such as BIO-Europe, BIO USA, and the JP Morgan Healthcare Conference this year. The company is also pursuing a merger with Kosdaq-listed Solux, with the scheduled date set for January 20, 2026.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
